LCN2 and Stroke: Administration of LCN-2 mAb prior to full post-stroke LCN-2 elevation reduced the levels of LCN-2 and pro-inflammatory mediators (iNOS, IL-6, CCL2, and CCL9) and resulted in neutrophil infiltration, BBB leakage, cerebral infarction induction, and improved functional outcomes after stroke (Wang Z. et al., 2020).